A number of urine based tumor markers are available preclinically for bladder cancer. The diagnosis of bladder cancer currently relies on identifying malignant cells in the urine and subsequently visualizing the tumor on cystoscopy. This diagnosis is further confirmed by transurethral resection or biopsy. However their sensitivity rate is highly poor for low-grade bladder neoplasms. Therefore more sensitive tumor markers are needed. On the other hand, easy applicable and cheap molecular diagnostic tools might be better for monitoring illness. In this review new molecular markers are discussed to understand their comparisons easily.